GB1533205A - Plasmin fractions and complexes thereof - Google Patents

Plasmin fractions and complexes thereof

Info

Publication number
GB1533205A
GB1533205A GB38933/77A GB3893377A GB1533205A GB 1533205 A GB1533205 A GB 1533205A GB 38933/77 A GB38933/77 A GB 38933/77A GB 3893377 A GB3893377 A GB 3893377A GB 1533205 A GB1533205 A GB 1533205A
Authority
GB
United Kingdom
Prior art keywords
plasmin
plasminogen
complex
streptokinase
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB38933/77A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REESE RES FOUNDATION M
Original Assignee
REESE RES FOUNDATION M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REESE RES FOUNDATION M filed Critical REESE RES FOUNDATION M
Publication of GB1533205A publication Critical patent/GB1533205A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB38933/77A 1976-09-24 1977-09-19 Plasmin fractions and complexes thereof Expired GB1533205A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/726,142 US4082612A (en) 1976-09-24 1976-09-24 Plasminogen activator complex

Publications (1)

Publication Number Publication Date
GB1533205A true GB1533205A (en) 1978-11-22

Family

ID=24917422

Family Applications (1)

Application Number Title Priority Date Filing Date
GB38933/77A Expired GB1533205A (en) 1976-09-24 1977-09-19 Plasmin fractions and complexes thereof

Country Status (10)

Country Link
US (1) US4082612A (enExample)
JP (1) JPS5352606A (enExample)
CA (1) CA1094449A (enExample)
CH (2) CH637991A5 (enExample)
DE (1) DE2742529C2 (enExample)
DK (1) DK421577A (enExample)
FR (1) FR2365583A1 (enExample)
GB (1) GB1533205A (enExample)
NL (1) NL7710451A (enExample)
SE (3) SE442304B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2121685A (en) * 1982-04-30 1984-01-04 Kaken Pharma Co Ltd Protease compositions for treating blood lipids abnormality and arteriosclerosis

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
EP0109653A3 (en) * 1982-11-17 1986-01-29 Otsuka Pharmaceutical Co., Ltd. Process for preparing urokinase complex
JPS60136520A (ja) * 1983-12-23 1985-07-20 Otsuka Pharmaceut Co Ltd フイブリン吸着性ウロキナ−ゼ複合体
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
US4880776A (en) * 1983-12-24 1989-11-14 Beecham Group P.L.C. Plasmin A-chain urokinase B-chain hybrid protein
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
DE3833936C1 (enExample) * 1988-10-05 1989-09-21 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) * 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
NZ589557A (en) * 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865692A (en) * 1974-01-11 1975-02-11 Abbott Lab Method for making highly potent plasminogen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2121685A (en) * 1982-04-30 1984-01-04 Kaken Pharma Co Ltd Protease compositions for treating blood lipids abnormality and arteriosclerosis

Also Published As

Publication number Publication date
FR2365583A1 (fr) 1978-04-21
FR2365583B1 (enExample) 1981-07-10
SE8301795D0 (sv) 1983-03-30
SE454048B (sv) 1988-03-28
CH637991A5 (de) 1983-08-31
SE454047B (sv) 1988-03-28
DE2742529C2 (de) 1984-01-05
SE8301795L (sv) 1983-03-30
US4082612A (en) 1978-04-04
SE442304B (sv) 1985-12-16
DE2742529A1 (de) 1978-03-30
CH637992A5 (de) 1983-08-31
SE7710653L (sv) 1978-03-25
DK421577A (da) 1978-03-25
JPS5352606A (en) 1978-05-13
NL7710451A (nl) 1978-03-29
CA1094449A (en) 1981-01-27
SE8301794D0 (sv) 1983-03-30

Similar Documents

Publication Publication Date Title
GB1533205A (en) Plasmin fractions and complexes thereof
Silverstein et al. Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation.
Fletcher et al. Fibrinolytic mechanisms and the development of thrombolytic therapy
Tran-Thang et al. Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots.
Adelman et al. Proteolysis of platelet glycoprotein lb by plasmin is facilitated by plasmin lysine-binding regions
NO922237D0 (no) Proteiner og nukleinsyrer
Silverstein et al. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin.
DK0477274T3 (da) Faktor Xa baserede antikoaguleringspræparater
JPS6236502B2 (enExample)
Knudsen et al. Matrix plasminogen activator inhibitor. Modulation of the extracellular proteolytic environment.
ATE108206T1 (de) Gewebe-plasminogenaktivator.
DE3751224D1 (de) Diagnostischer test für plasminogenaktivatoren vom gewebs- und urokinasetyp und dafür kodierende gene.
Liu et al. A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase.
Robbins The human plasma fibrinolytic system: regulation and control
Petersen et al. Immunosuppressive properties of electrophoretically" slow" and" fast" form alpha 2-macroglobulin. Effects on cell-mediated cytotoxicity and (allo-) antigen-induced T cell proliferation.
Davidson et al. Synthetic fibrinolytic agents
Harpel Circulating inhibitors of human plasma kallikrein
KR880007731A (ko) 하이브리드 단백질
Chandra et al. Radiolabelled ATIII as a probe for the detection of activation of blood coagulation invivo
EP0339505A3 (en) Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
HUT59610A (en) Process for producing pharmaceutical compositions for solving blood clot containing t-pa without glycosilyzing
Young et al. Sustained lymphatic delivery of fibrinogen after induced afibrinogenemia
ATE78292T1 (de) Plasminogen-aktivator und thrombolytische zusammensetzung.
Prentice et al. Evaluation of a new preparation of urokinase
KR890701732A (ko) 개량형 조직 플라스미노겐 활성화 인자

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee